Overview

BREADS: Breast Adjuvant Diet Study

Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
0
Participant gender:
Female
Summary
This is a randomized controlled trial of a 6-month extreme carbohydrate restricted diet (20 grams total carbs/day) via phone counseling with dietitian plus aromatase inhibitor therapy vs. 6-month control with aromatase inhibitor therapy alone. Visits will occur at screening, 3 months, and 6 months. Anthropomorphic measurements (such as heart rate, weight, and body measurement) and questionnaires will be taken at all three visits. After screening, patients will be randomized to receive the carbohydrate restricted diet coaching immediately (Arm A) or to a control group (Arm B). Patients randomized to Arm A will receive weekly calls for the first 3 months of the intervention, then biweekly calls for the last 3 months of the intervention from the study dietitian. Total duration of the study is expected to be 3 years, though each patient's participation will be approximately 6 months.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Farin Amersi
Treatments:
Aromatase Inhibitors
Criteria
Inclusion Criteria:

- Histologically confirmed breast cancer

- 4.1.2 Planning to start adjuvant hormonal therapy using an aromatase inhibitor or has
started adjuvant hormonal therapy using an aromatase inhibitor within 14 days of
randomization.

- Able to read, write, and understand English

- BMI ≥ 24 kg/m2

- Age ≥ 18 years

- If Her-2 positive, completed Herceptin therapy prior to enrollment

- ER and/or PR positive (defined as having ≥ 1% staining for ER and/or PR on IHC)

- Post-menopausal

- The absence of menstrual cycles in women who have not undergone hysterectomy for
at least 12 months preceding cancer diagnosis OR

- History of a bilateral oophorectomy OR

- History of a hysterectomy and age >55 OR

- No menses for <1 year with FSh and estradiol levels in postmenopausal range
according to institutional standards

- ECOG Performance Status 0 or 1

- Female

- Written informed consent obtained from subject and ability for subject to comply with
requirements of the study

Exclusion Criteria:

- Use of hormonal therapy other than aromatase inhibitors

- History of other malignancy within the past 5 years, except for malignancies with a >
95% likelihood of cure (e.g. thyroid cancer, non-melanoma skin cancer)

- Already consuming a severe carbohydrate restricted (<20 g carbohydrates per day) diet
or vegetarian diet

- Plans to start chemotherapy or HER2 targeted therapy

- Medical comorbidities that in the opinion of the investigator limits the patient's
ability to complete the study

- Symptomatic metastases (Metastases allowed if asymptomatic)

- Current use of appetite suppressant medications

- Current use of any weight loss medications including herbal weight loss supplements or
if patients are enrolled in a diet/weight loss program